Multiple myeloma and bone marrow mesenchymal stem cells’ crosstalk: Effect on translation initiation

Molecular Carcinogenesis

Volumn 55, Issue 9, 2016, Pages 1343-1354

  Attar Schneider, Oshrat ^a,b   Zismanov, Victoria ^a,b   Dabbah, Mahmoud ^a,b   Tartakover Matalon, Shelly ^a,b   Drucker, Liat ^a,b   Lishner, Michael ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

cancer microenvironment; eIF4E; eIF4GI; mesenchymal stem cells; multiple myeloma; translation initiation

Indexed keywords

INITIATION FACTOR 4E; INITIATION FACTOR 4G;

ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL DEATH; CELL FATE; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSLATION INITIATION; TUMOR MICROENVIRONMENT;

EID: 84985034222     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22378     Document Type: Article

References (50)

1. Brink R. New friends for bone marrow plasma cells. Nat Immunol 2011; 12:115–117.
2. Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001; 91:1219–1230.
3. Basak GW, Srivastava AS, Malhotra R, Carrier E. Multiple myeloma bone marrow niche. Curr Pharm Biotechnol 2009; 10:345–346.
4. Garayoa M, Garcia JL, Santamaria C, et al. Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors. Leukemia 2009; 23:1515–1527.
5. Dezorella N, Pevsner-Fischer M, Deutsch V, et al. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Exp Cell Res 2009; 315:1904–1913.
6. Robert F, Pelletier J. Translation initiation: A critical signalling node in cancer. Expert Opin Ther Targets 2009; 13:1279–1293.
7. Thornton S, Anand N, Purcell D, Lee J. Not just for housekeeping: Protein initiation and elongation factors in cell growth and tumorigenesis. J Mol Med 2003; 81:536–548.
8. Agnelli L, Fabris S, Bicciato S, et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007; 136:565–573.
9. Adeli K. Translational control mechanisms in metabolic regulation: Critical role of RNA binding proteins, microRNAs, and cytoplasmic RNA granules. Am J Physiol Endocrinol Metab 2011; 301:E1051–E1064.
10. Barnhart B, Simon M. Taking aim at translation for tumor therapy. J Clin Invest 2007; 117:2385–2388.
11. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471:467–472.
12. Montanaro L, Pandolfi P. Initiation of mRNA translation in oncogenesis. Cell Cycle 2004; 3:1387–1389.
13. Clutter SD, Fortney JE, Gibson LF. Chemotherapy disrupts activity of translational regulatory proteins in bone marrow stromal cells. Exp Hematol 2006; 34:1522–1531.
14. Ramirez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. EIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol 2008; 181:293–307.
15. Cenci S, Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett 2007; 581:3652–3657.
16. Shatsky IN, Dmitriev SE, Andreev DE, Terenin IM. Transcriptome-wide studies uncover the diversity of modes of mRNA recruitment to eukaryotic ribosomes. Crit Rev Biochem Mol Biol 2014; 49:164–177.
17. Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest 2012; 92:178–190.
18. Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Lishner M. Targeting eIF4GI translation initiation factor affords an attractive therapeutic strategy in multiple myeloma. Cell Signal 2014.
19. Zismanov V, Attar-Schneider O, Lishner M, Heffez Aizenfeld R, Tartakover Matalon S, Drucker L. Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E. Int J Oncol 2015; 46:860–870.
20. Drucker L, Afensiev F, Radnay J, Shapira H, Lishner M. Co-administration of simvastatin and cytotoxic drugs is advantageous in myeloma cell lines. Anticancer Drugs 2004; 15:79–84.
21. Osadchy A, Drucker L, Radnay J, Shapira H, Lishner M. Microenvironment factors do not afford myeloma cell lines protection from simvastatin. Eur J Haematol 2004; 73:183–190.
22. Zismanov V, Lishner M, Tartakover-Matalon S, Radnay J, Shapiro H, Drucker L. Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer 2009; 101:1402–1409.
23. Dolfi SC, Chan LL, Qiu J, et al. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab 2013; 1:20.
24. Zismanov V, Drucker L, Attar-Schneider O, Matalon ST, Pasmanik-Chor M, Lishner M. Tetraspanins stimulate protein synthesis in myeloma cell lines. J Cell Biochem 2012; 113:2500–2510.
25. Qiao L, Xu Z, Zhao T, et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008; 18:500–507.
26. Shinagawa K, Kitadai Y, Tanaka M, et al. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int J Cancer 2010; 127:2323–2333.
27. Tsukamoto S, Honoki K, Fujii H, et al. Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int J Oncol 2012; 40:163–169.
28. Wei Z, Chen N, Guo H, et al. Bone marrow mesenchymal stem cells from leukemia patients inhibit growth and apoptosis in serum-deprived K562 cells. J Exp Clin Cancer Res 2009; 28:141.
29. Khakoo AY, Pati S, Anderson SA, et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J Exp Med 2006; 203:1235–1247.
30. Atsuta I, Liu S, Miura Y, et al. Mesenchymal stem cells inhibit multiple myeloma cells via the Fas/Fas ligand pathway. Stem Cell Res Ther 2013; 4:111.
31. Zhang XH, Sun Y, Wang ZY, Huang ZP, Fu JX. [Alterations of connexin 43 expression and SDF-1alpha secretion of bone marrow mesenchymal stem cells co-cultured with myeloma cells]. Zhonghua Xue Ye Xue Za Zhi 2013; 34:788–793.
32. Noll JE, Williams SA, Tong CM, et al. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica 2014; 99:163–171.
33. Ciavarella S, Caselli A, Savonarola A, Tamma AV, Tucci M, Silvestris F. Cytotherapies in multiple myeloma: A complementary approach to current treatments?. Expert Opin Biol Ther 2013; 13:S23–S34.
34. Pevsner-Fischer M, Levin S, Hammer-Topaz T, et al. Stable changes in mesenchymal stromal cells from multiple myeloma patients revealed through their responses to Toll-like receptor ligands and epidermal growth factor. Stem Cell Rev 2012; 8:343–354.
35. Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: Characterization, origin, and tumor-promoting effects. Clin Cancer Res 2012; 18:342–349.
36. Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo. Stem Cells 2012; 30:266–279.
37. Andre T, Meuleman N, Stamatopoulos B, et al. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS ONE 2013; 8:e59756.
38. Corre J, Mahtouk K, Attal M, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21:1079–1088.
39. Waldman YY, Geiger T, Ruppin E. A genome-wide systematic analysis reveals different and predictive proliferation expression signatures of cancerous vs. non-cancerous cells. PLoS Genet 2013; 9:e1003806.
40. Loreni F, Mancino M, Biffo S. Translation factors and ribosomal proteins control tumor onset and progression: How?. Oncogene 2014; 33:2145–2156.
41. Cope CL, Gilley R, Balmanno K, et al. Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci 2014; 127:788–800.
42. Shin S, Wolgamott L, Roux PP, Yoon SO. Casein kinase 1epsilon promotes cell proliferation by regulating mRNA translation. Cancer Res 2014; 74:201–211.
43. Feoktistova K, Tuvshintogs E, Do A, Fraser CS. Human eIF4E promotes mRNA restructuring by stimulating eIF4A helicase activity. Proc Natl Acad Sci USA 2013; 110:13339–13344.
44. Luo B, Lee AS. The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 2013; 32:805–818.
45. Alenzi FQ. Links between apoptosis, proliferation and the cell cycle. Br J Biomed Sci 2004; 61:99–102.
46. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. EIF4E-from translation to transformation. Oncogene 2004; 23:3172–3179.
47. Bitterman PB, Polunovsky VA. Translational control of cell fate: From integration of environmental signals to breaching anticancer defense. Cell Cycle 2012; 11:1097–1107.
48. Contreras V, Friday AJ, Morrison JK, Hao E, Keiper BD. Cap-independent translation promotes C. elegans germ cell apoptosis through Apaf-1/CED-4 in a caspase-dependent mechanism. PLoS ONE 2011; 6:e24444.
49. Keramidas M, de Fraipont F, Karageorgis A, et al. The dual effect of mscs on tumour growth and tumour angiogenesis. Stem Cell Res Ther 2013; 4:41.
50. Howard A, Rogers AN. Role of translation initiation factor 4G in lifespan regulation and age-related health. Ageing Res Rev 2014; 13C:115–124.